Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | GLA | P06280 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | THPO | P40225 | 3/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 3/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL27562 | 0.95 | SCNN1A (0.58) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL15517241 | 0.95 | SCNN1A (0.58) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL29129215 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL21524891 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL3253482 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL1441814 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL17986365 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL41233 | 0.94 | SCNN1A (0.57) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL1487484 | 0.92 | SCNN1A (0.56) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A | |
| Amiloride SCHEMBL317394 | 0.92 | SCNN1A (0.56) | SCNN1AALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| CN-103933046-B | A kind of anti-pancreatic cancer medicament composition and its application, medicine box and package | 复旦大学 | 2018-10-26 | — | — | CN | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| US-7923448-B2 | A P2X7 purine receptor antagonist, selected from 1-[N,O-bis(5-Isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine, hexamethylene amiloride, oxidized ATP, and brilliant blue G, is administered by injection, orally or transdermally; inhibiting ATP-triggered cell death; antiischemic agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-04-12 | — | — | US | claimed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| US-20050164975-A1 | Purine receptor inhibition as a therapeutic strategy in spinal cord and brain | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-28 | — | — | US | claimed |
| WO-2005041892-A2 | PURINE RECEPTOR INHIBITION AS A THERAPEUTIC STRATEGY IN SPINAL CORD AND BRAIN | CORNELL RESEARCH FOUNDATION, INC (US) | 2005-05-12 | — | — | WO | claimed |
| US-5693462-A | MIXTURE OF A BICARBONATE, AN AMILORIDE-CONTAINING COMPOUND, WATER AND ADENOSINE, OPTIONAL OTHER CONSTITUENTS | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1997-12-02 | — | — | US | claimed |
| EP-0797384-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY doing business as Carolinas Medical Center (US) | 1997-10-01 | — | — | EP | claimed |
| US-5554497-A | AMILORIDE | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-09-10 | — | — | US | claimed |
| WO-1996018293-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-06-20 | — | — | WO | claimed |
| US-20260144871-A1 | Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof | CELULARITY INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | CELULARITY INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-5554497-A | AMILORIDE | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-09-10 | — | — | US | disclosed |
| US-5554497-A | AMILORIDE | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996018293-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1996018293-A1 | ORGAN TRANSPLANT SOLUTIONS AND METHOD FOR TRANSPLANTING AN ORGAN | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295776-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | PBK, PIGK, CD74 | SCNN1A 797/4885ALDH1A1 4671/4885SMN1; SMN2 3127/4885 |
| US-20250276063-A1 | PLACENTA-DERVIED NK CELLS AS A SENOL YTIC FOR THERAPEUTIC AND OTHER USES | PBK, CD47, GZMB | SCNN1A 2288/4885ALDH1A1 3849/4885SMN1; SMN2 3390/4885 |
| US-20260144871-A1 | Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof | IL15RA, IL15, PBK | SCNN1A 567/4885ALDH1A1 4343/4885SMN1; SMN2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.